Scholarlink

<p>To quantify the impact of Glucagon-like peptide1 receptor-agonists (GLP1-RAs) on asthma control, we analysed people with asthma and obesity, using the Optimum Patient Care Research Database (OPCRD). We identified 10,111 GLP1-RA exposed people and 50,555 unexposed controls. The exposed cohort had higher BMI and more uncontrolled asthma [risk domain asthma control (RDAC) and overall asthma control (OAC)]. The exposed cohort lost more weight and had improved asthma control for both RDAC (odds ratio 2.11 95% CI 1.90–2.36) and OAC (OR 2.10, 95%CI 1.81–2.45) scores. GLP1-RA drugs appear to improve asthma control for people with obesity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Real-World Impact of Glucagon-Like Peptide 1 Receptor Agonists on Asthma Control in People with High-Risk Asthma and Obesity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月8日

查看全文
  • Alan Kaplan,
  • Heath Heatley,
  • John Townend,
  • Derek Skinner,
  • Victoria Carter,
  • Richard Hubbard,
  • Tan Tze Lee,
  • Mariko Siyue Koh,
  • David Price

摘要

To quantify the impact of Glucagon-like peptide1 receptor-agonists (GLP1-RAs) on asthma control, we analysed people with asthma and obesity, using the Optimum Patient Care Research Database (OPCRD). We identified 10,111 GLP1-RA exposed people and 50,555 unexposed controls. The exposed cohort had higher BMI and more uncontrolled asthma [risk domain asthma control (RDAC) and overall asthma control (OAC)]. The exposed cohort lost more weight and had improved asthma control for both RDAC (odds ratio 2.11 95% CI 1.90–2.36) and OAC (OR 2.10, 95%CI 1.81–2.45) scores. GLP1-RA drugs appear to improve asthma control for people with obesity.